CRISPR Therapeutics AG (NASDAQ:CRSP) Holdings Lifted by Private Advisor Group LLC

Private Advisor Group LLC raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 27.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,418 shares of the company's stock after purchasing an additional 23,382 shares during the quarter. Private Advisor Group LLC owned about 0.13% of CRISPR Therapeutics worth $3,689,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Capital International Investors boosted its holdings in shares of CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after purchasing an additional 816,789 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. Vanguard Group Inc. increased its holdings in CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after purchasing an additional 10,579 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in CRISPR Therapeutics by 55.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after purchasing an additional 464,936 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in CRISPR Therapeutics by 12.0% in the 4th quarter. Bank of America Corp DE now owns 1,211,509 shares of the company's stock valued at $47,685,000 after purchasing an additional 129,746 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Activity

In related news, insider Naimish Patel sold 3,932 shares of the stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the sale, the insider owned 6,068 shares in the company, valued at $218,083.92. This represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Simeon George acquired 989,812 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The shares were acquired at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the purchase, the director owned 1,730,179 shares of the company's stock, valued at $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Stock Down 2.0%

Shares of CRSP traded down $1.30 during midday trading on Friday, hitting $64.76. The company had a trading volume of 2,910,303 shares, compared to its average volume of 4,356,798. The company's 50 day moving average price is $47.56 and its 200 day moving average price is $42.73. The stock has a market cap of $5.59 billion, a price-to-earnings ratio of -14.33 and a beta of 1.82. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same quarter in the prior year, the company posted ($1.43) earnings per share. The company's revenue was up 71.6% on a year-over-year basis. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several recent research reports. Chardan Capital reiterated a "buy" rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Thursday, June 26th. The Goldman Sachs Group lowered their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Piper Sandler reiterated an "overweight" rating and issued a $105.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Bank of America lowered their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday. Finally, JMP Securities reiterated a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $71.31.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.